MN-25

MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg>[1].

Product Specifications

CAS Number

[501926-82-5]

UNSPSC

12352005

Target

Cannabinoid Receptor; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mn-25.html

Smiles

C[C@]1(C[C@](CC1)([H])C2(C)C)[C@@H]2NC(C3=CN(C4=C(OC)C=CC=C43)CCN5CCOCC5)=O

Molecular Formula

C26H37N3O3

Molecular Weight

439.59

References & Citations

[1]Stephen T Wrobleski, et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem. 2003 May 22;46 (11) :2110-6.